Hi Folks, I haven’t posted here for a while but following closely the final closing of the NVS deal.
If we managed to analyze the data in 2 to 3 months, I believe NVS can do likewise in the same time frame. IMO the “other conditions” our CEO refers to are included in the minutes of the meeting. Given their importance he chose not reveal the strongpoints of the discussion in the latest announcement. Verbatim disclosure is safer -protects from down ramping- and precise. It will define the path forward, related cost and hence accurately the milestone payments (ref Grunenthal agreement).
To my mind it’s not longer a question of if or when the agreement will be closed, rather how much NVS will have to pay us. This in itself takes time as this type of agreement is always verbose, full of “notwithstanding”, “provided that”, “to the extent”… all subject to interpretation. More a legal matter than science since the trial results are nothing short of stellar!
Have a nice Sunday (11:30 here) and stay safe,
Cheers
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-10344
-
- There are more pages in this discussion • 7,918 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B |
Open | High | Low | Value | Volume |
$1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 24758 | $1.49 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.49 | 73626 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10033 | 1.485 |
4 | 53700 | 1.480 |
1 | 770 | 1.475 |
3 | 62048 | 1.460 |
1 | 50000 | 1.455 |
Price($) | Vol. | No. |
---|---|---|
1.490 | 21995 | 1 |
1.505 | 24000 | 1 |
1.510 | 13666 | 2 |
1.515 | 99798 | 1 |
1.520 | 27250 | 3 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
MSB (ASX) Chart |